In summary, this research represents a breakthrough in paclitaxel biosynthesis by identifying missing enzymes, revealing new biochemical mechanisms, and successfully reconstituting baccatin III in a heterologous system. This lays the foundation for improving the production of paclitaxel through synthetic biology and metabolic engineering. The paper by provides a comprehensive overview of recent advancements in understanding the intricate metabolic network of paclitaxel biosynthesis. Paclitaxel, a complex diterpenoid compound produced by the yew tree (genus *Taxus*), is a highly effective anticancer agent used to treat various cancers such as breast, lung, prostate, and ovarian cancers. Due to its complex structure and low natural abundance, there has been significant interest in elucidating its biosynthetic pathway to enable sustainable production through metabolic engineering.